دورية أكاديمية
Incidence and Clearance of Anal Human Papillomavirus Infection in 16 164 Individuals, According to Human Immunodeficiency Virus Status, Sex, and Male Sexuality: An International Pooled Analysis of 34 Longitudinal Studies.
| العنوان: | Incidence and Clearance of Anal Human Papillomavirus Infection in 16 164 Individuals, According to Human Immunodeficiency Virus Status, Sex, and Male Sexuality: An International Pooled Analysis of 34 Longitudinal Studies. |
|---|---|
| المؤلفون: | Wei F; Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France., Goodman MT; Cancer Prevention and Control Program, Cedars Cancer, Cedars-Sinai Medical Center, Los Angeles, California, USA., Xia N; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China., Zhang J; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China., Giuliano AR; Center for Immunization and Infection Research in Cancer (CIIRC), Moffitt Cancer Center, Tampa, Florida, USA., D'Souza G; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Hessol NA; Department of Clinical Pharmacy, University of California San Francisco, California, USA., Schim van der Loeff MF; Department of Infectious Diseases, GGD Amsterdam, Amsterdam, Netherlands., Dai J; School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China., Neukam K; Unidad Clínica de Enfermedades Infecciosas y Medicina Preventiva, UCEIMP, Instituto de Biomedicina de Sevilla, CSIC, Universidad de Sevilla, Hospital Universitario Virgen del Rocío, Seville, Spain., de Pokomandy A; Chronic Viral Illness Service, McGill University Health Centre and Department of Family Medicine, McGill University, Montreal, Quebec, Canada., Poynten IM; The Kirby Institute, University of New South Wales, Kensington, Sydney, New South Wales, Australia., Geskus RB; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.; Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK., Burgos J; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Vall d'Hebron Institut de Recerca (VHIR), Universitat Autónoma de Barcelona, Barcelona, Spain., Etienney I; Proctology, Diaconesses-Croix Saint Simon Hospital, Paris, France., Moscicki AB; Department of Pediatrics, University of California, Los Angeles, California, USA., Donà MG; Sexually Transmitted Infections (STI)/HIV Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy., Gillison ML; Thoracic Head and Neck Medical Oncology Department, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Nyitray AG; Center for AIDS Intervention Research and Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Nowak RG; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Yunihastuti E; Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia., Zou H; School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China.; Kirby Institute, University of New South Wales, Sydney, Australia., Hidalgo-Tenorio C; Early Clinical Trial Unit. Biosanitary Institute (IBS.Granada). Infectious Diseases Unit. University Hospital Virgen de las Nieves, Granada, Spain., Phanuphak N; Institute of HIV Research and Innovation, Bangkok, Thailand., Molina JM; Department of Infectious diseases, University of Paris Cité, St-Louis Hospital, Paris, France., Schofield AM; Institute of Cancer Sciences, The University of Manchester, Manchester, UK., Kerr S; HIV-NAT, Thai Red Cross AIDS Research Centre, and Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand., Fan S; School of Public Health, Southwest Medical University, Luzhou, China., Lu Y; School of Public Health, the Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang, China., Ong JJ; Central Clinical School, Monash University, Melbourne, Australia., Chikandiwa AT; Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Teeraananchai S; Department of Statistics, Faculty of Science, Kasetsart University, Bangkok, Thailand., Squillace N; Infectious Diseases Unit ASST-Monza, San Gerardo Hospital-University of Milano-Bicocca, Monza, Italy., Wiley DJ; School of Nursing, University of California, Los Angeles, California, USA., Palefsky JM; Department of Medicine, University of California, San Francisco, California, USA., Georges D; Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France., Alberts CJ; Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France., Clifford GM; Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France. |
| المصدر: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Feb 08; Vol. 76 (3), pp. e692-e701. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: Chicago, IL : The University of Chicago Press, c1992- |
| مواضيع طبية MeSH: | Papillomavirus Infections* , HIV Infections*/complications , HIV Infections*/epidemiology , Sexual and Gender Minorities* , Anus Diseases*/diagnosis , Anus Neoplasms*/complications, Male ; Humans ; Female ; Homosexuality, Male ; Human Papillomavirus Viruses ; Incidence ; Sexual Behavior ; Anal Canal ; Longitudinal Studies ; Human papillomavirus 16/genetics ; HIV ; Papillomaviridae/genetics |
| مستخلص: | Background: Understanding the natural history of anal high-risk human papillomavirus (hrHPV) infection is key for designing anal cancer prevention programs but has not been systematically characterized. Methods: We reanalyzed data from 34 studies including 16 164 individuals in 6 risk groups defined by human immunodeficiency virus (HIV) status, sex, and male sexuality: men who have sex with men (MSM) and people with HIV (MSMWH), HIV-negative MSM, women with HIV (WWH), HIV-negative women, men who have sex with women (MSW) with HIV (MSWWH), and HIV-negative MSW. We used Markov models to estimate incidence and clearance of 13 hrHPV types and their determinants. Results: Human papillomavirus (HPV) 16 had the highest incidence-clearance ratio of the hrHPV types. MSMWH had the highest hrHPV incidence (eg, 15.5% newly HPV-16 infected within 2 years), followed by HIV-negative MSM (7.5%), WWH (6.6%), HIV-negative women (2.9%), MSWWH (1.7%), and HIV-negative MSW (0.7%). Determinants of HPV-16 incidence included HIV status and number of sexual partners for MSM, women, and MSW, and anal sex behavior for MSM only. HPV-16 clearance was lower for people with HIV (PWH) and lower for prevalent than incident infection. Among MSM, increasing age was associated with lower clearance of prevalent, but not incident, HPV-16 infection. Conclusions: This robust and unifying analysis of anal hrHPV natural history is essential to designing and predicting the impact of HPV vaccination and HPV-based screening programs on anal cancer prevention, particularly in MSM and PWH. Importantly, it demonstrates the higher carcinogenic potential of longstanding anal prevalent hrHPV infection than more recent incident infection. Competing Interests: Potential conflicts of interest. A. R. G. received support from Merck & Co and Moderna, outside the submitted work, and reports consulting fees from Merck & Co. G. D. received support to her institution from the National Institutes of Health (NIH) for this work. N. A. H. received a grant to her institution from NIH for this work. M. F. S. v. d. L. has served on an advisory board for Merck & Co. K. N. received a Miguel Servet II senior researcher grant contract (CPII18/00033) from the Instituto de Salud Carlos III (Madrid, Spain), outside the submitted work. J. B. received financial compensation for lectures, consultancy work, educational activities from Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, and ViiV Healthcare and received support for attending meetings from Gilead Sciences, outside the submitted work. M. L. G. received support from National Institute of Dental and Craniofacial Research for and outside the submitted work; has received research funding from Genocea Biosciences, Bristol-Myers Squibb, Genentech, Kur, Cullinan Labs, and Agenus; served as a consultant for Istari Oncology, LLX Solutions, Kura Oncology, Mirati Therapeutics, BioNtech, Bristol-Myers Squibb, Bicara Therapeutics, Bayer Healthcare Pharmaceutics, Genocea Biosciences, Shattucks Labs, EMD Serono, Debiopharm, Merck & Co, Ipsen Biopharmaceuticals, Gilead Sciences, and Coherus; served a speaker/preceptorship role for OncLive and Roche Scientific; received support for attending meetings from American Association for Cancer Research (AACR); has an issued patent as sponsor-investigator for pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA for a clinical protocol entitled “An open-label phase one study of the safety with stage III or IV HPV16-positive head and neck squamous cell carcinoma”; has pending patents for “Oral HPV infection detection for oral cancer screening and diagnosis” and “HPV mRNA detection on oral cytology specimens for diagnosis and screening for oral cancer”; served on advisory committees for Seagen, Sensei Biotherapeutics, SQZBiotech, BioMimetix and Kura; and has stock options for Sensei. A. G. N. received grants from National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute (NCI), NIH, and Merck & Co, awarded to his institution and related to the submitted work; received grants from NCI, NIH, awarded to his institution, outside the submitted work; received support for attending meetings (payment for hotel at conference) from the European Research Organisation on Genital Infection and Neoplasia; and received donated swabs and vials for research from COPAN Diagnostics. R. G. N. received funding from NCI, NIH (grant K07CA225403), paid to her institution. E. Y. received to her institution, for this work, in support from subawards from amfAR, The Foundation for AIDS Research (grants 108520-52-IGTA and 108893-55-IPTA), with funds provided by Life Ball and Verein Aids Life (AIDS LIFE). The Asia Pacific HIV Research Collaboration is an initiative of TREAT Asia, a program of amfAR, The Foundation for AIDS Research, with support from the NIAID, NIH, as part of the International Epidemiologic Databases to Evaluate AIDS (IeDEA). These subgrants were supported with funds provided by NIH cooperative agreement 5U01AI0699007-07 and a supplement to NIH cooperative agreement 5U01AI0699007-08. J. M. M. received research grants from Gilead to his institution for the present work and personal consulting fees from Gilead, Merck & Co, and ViiV. JJO received funds both to himself and to his institution from Australian National Health and Medical Research Council, outside the submitted work; served as Board Director of Australian Society of HIV, viral hepatitis and sexual heath medicine (ASHM), Australian Federation of AIDS Organizations (AFAO). N. S. received personal consulting fees from ViiV Healthcare and honoraria from Gilead Sciences. D. J. W. received funding from the NCI, NIH (R01CA169508-01A1 [principal investigator (PI), D. J. W.] and 5UM1AI035043-23 (PI, G. D.; site PI, D. J. W.; both studies: data collection, specimen processing, laboratory tests). J. M. P. reports grants or contracts paid to the institution from Merck and Co, outside the submitted work; consulting fees paid to self from Vir Biotechnologies and Antiva Biosciences; payment or honoraria from Merck and Co; support for attending meetings and/or travel paid to self from Merck and Co; and stock or stock options from Virion Therapeutics and Vir Biotechnology. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.) |
| References: | Emerg Infect Dis. 2020 Oct;26(10):2387-2393. (PMID: 32946717) Clin Infect Dis. 2021 Mar 1;72(5):853-861. (PMID: 32342984) Clin Infect Dis. 2019 Apr 24;68(9):1556-1565. (PMID: 30169621) Lancet HIV. 2021 Sep;8(9):e531-e543. (PMID: 34339628) Viruses. 2021 Jan 20;13(2):. (PMID: 33498165) Papillomavirus Res. 2019 Dec;8:100187. (PMID: 31600572) Lancet Infect Dis. 2018 Feb;18(2):198-206. (PMID: 29158102) Cancer Epidemiol. 2016 Jun;42:124-32. (PMID: 27107173) Lancet Oncol. 2011 Sep;12(9):862-70. (PMID: 21865087) J Infect Dis. 2019 Jan 29;219(4):590-598. (PMID: 30239749) Lancet Glob Health. 2020 Feb;8(2):e180-e190. (PMID: 31862245) Clin Infect Dis. 2014 Mar;58(6):804-11. (PMID: 24368624) IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441. (PMID: 23189750) Vaccine. 2020 Feb 5;38(6):1315-1331. (PMID: 31836255) Clin Microbiol Infect. 2016 Dec;22(12):1004.e1-1004.e7. (PMID: 27585942) Int J Cancer. 2021 Jan 1;148(1):38-47. (PMID: 32621759) Lancet Public Health. 2016 Nov;1(1):e8-e17. (PMID: 29253379) Cancer. 2004 Jul 15;101(2):270-80. (PMID: 15241823) J Infect Dis. 2016 Oct 15;214(8):1180-7. (PMID: 27489298) Clin Infect Dis. 2018 Oct 15;67(9):1339-1346. (PMID: 29659751) J Infect Dis. 2007 Jun 1;195(11):1582-9. (PMID: 17471427) N Engl J Med. 2022 Jun 16;386(24):2273-2282. (PMID: 35704479) J Infect Dis. 2020 Apr 7;221(9):1488-1493. (PMID: 31754686) J Infect Dis. 2023 Feb 14;227(4):488-497. (PMID: 35325151) AIDS. 2016 Jan 2;30(1):37-44. (PMID: 26355673) N Engl J Med. 2011 Oct 27;365(17):1576-85. (PMID: 22029979) Sci Rep. 2022 Jan 7;12(1):184. (PMID: 34996988) Lancet Infect Dis. 2021 Oct;21(10):1448-1457. (PMID: 34043963) Int J Cancer. 2010 Feb 1;126(3):684-91. (PMID: 19609952) AIDS. 2016 Jan 2;30(1):121-32. (PMID: 26474302) |
| معلومات مُعتمدة: | 001 International WHO_ World Health Organization; K07 CA225403 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: HIV; HPV; anus; clearance; incidence |
| تواريخ الأحداث: | Date Created: 20220723 Date Completed: 20230210 Latest Revision: 20240324 |
| رمز التحديث: | 20240324 |
| مُعرف محوري في PubMed: | PMC10226739 |
| DOI: | 10.1093/cid/ciac581 |
| PMID: | 35869839 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/ciac581 |